About: Icosapent ethyl     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
http://linked.open...gbank/description
  • Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is used as adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL). FDA approved on July 26, 2012. (en)
http://linked.open...y/drugbank/dosage
http://linked.open...generalReferences
  • # Ballantyne CM, Braeckman RA, Soni PN: Icosapent ethyl for the treatment of hypertriglyceridemia. Expert Opin Pharmacother. 2013 May 24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23701295 # FDA label (en)
http://linked.open...gy/drugbank/group
  • approved (en)
  • nutraceutical (en)
http://linked.open...drugbank/halfLife
  • The half life of EPA is 89 hours. (en)
http://linked.open...ugbank/indication
  • Icosapent ethyl is used as adjunct therapy to reduce triglyceride (TG) levels in adults with severe (>500 mg/dL) hypertriglyceridemia. (en)
sameAs
Title
  • Icosapent ethyl (en)
adms:identifier
http://linked.open...mechanismOfAction
  • Studies suggest that EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity. (en)
http://linked.open...y/drugbank/patent
http://linked.open...outeOfElimination
  • Icosapent ethyl is not renally excreted (en)
http://linked.open.../drugbank/synonym
  • EPA ethyl ester (en)
  • Epadel S (en)
  • Ethyl Eicosapentaenoate (en)
  • Ethyl icosapentate (en)
  • Ethyl-EPA (en)
  • Ethyl-Eicosapentaenoic Acid (en)
  • Icosapent ethyl (en)
  • Vascepa (en)
http://linked.open...drugbank/toxicity
  • Icosapent ethyl is generally well tolerated and adverse effects are unrelated to treatment. (en)
http://linked.open...umeOfDistribution
  • Steady state volume of distribution of active EPA is 88 L (en)
http://linked.open.../drug/hasAHFSCode
foaf:page
http://linked.open...ugbank/IUPAC-Name
http://linked.open...gy/drugbank/InChI
http://linked.open...Molecular-Formula
http://linked.open.../Molecular-Weight
http://linked.open...noisotopic-Weight
http://linked.open...y/drugbank/SMILES
http://linked.open.../Water-Solubility
http://linked.open...ogy/drugbank/logP
http://linked.open...ogy/drugbank/logS
http://linked.open...nd-Acceptor-Count
http://linked.open...-Bond-Donor-Count
http://linked.open...drugbank/InChIKey
http://linked.open...urface-Area--PSA-
http://linked.open...nk/Polarizability
http://linked.open...bank/Refractivity
http://linked.open...atable-Bond-Count
http://linked.open...ugbank/absorption
  • Icosapent ethyl is de-esterfied, converted into active EPA, and then absorbed in the small intestine. It reaches peak plasma concentration in 5 hours post-oral administration. Very little (<1%) is left circulating in the plasma as EPA incorporates into phospholipids, TG's, and cholesteryl esters. (en)
http://linked.open.../affectedOrganism
  • Humans and other mammals (en)
http://linked.open...casRegistryNumber
  • 86227-47-6 (en)
http://linked.open...drugbank/category
  • (en)
http://linked.open...rugbank/clearance
  • Total plasma clearance, EPA = 684 mL/hr (en)
http://linked.open...k/Bioavailability
http://linked.open...bank/Ghose-Filter
http://linked.open...nk/MDDR-Like-Rule
http://linked.open...k/Number-of-Rings
http://linked.open...siological-Charge
http://linked.open...bank/Rule-of-Five
http://linked.open...tional-IUPAC-Name
http://linked.open...-strongest-basic-
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 46 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software